Combinations of PD-1/PD-L1 inhibitors with different suppressors of molecules involved in intracellular signaling pathways, including kinase inhibitors, are currently being used to address multidrug resistance in breast cancer treatment [221,222]. The gene discussed is PDCD1; the disease is breast cancer.